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Primary testicular lymphoma is a rare and aggressive lymphoid malignancy, most often 
representing diffuse large B-cell lymphoma histologically. Tumor-associated macrophages and 
tumor-infiltrating lymphocytes have been associated with survival in diffuse large B-cell 
lymphoma, but their prognostic impact in primary testicular lymphoma is unknown. Here, we 
aimed to identify macrophages, their immunophenotypes and association with lymphocytes, and 
translate the findings into survival of patients with primary testicular lymphoma. We collected 
clinical data and tumor tissue from 74 primary testicular lymphoma patients, and used multiplex 
immunohistochemistry and digital image analysis to examine macrophage markers (CD68, CD163, 
and c-Maf), T-cell markers (CD3, CD4, and CD8), B-cell marker (CD20), and three checkpoint 
molecules (PD-L1, PD-L2, and PD-1). We demonstrate that a large proportion of macrophages 
(median 41%, range 0.08-99%) and lymphoma cells (median 34%, range 0.1-100%) express PD-L1. 




 macrophages correlates positively with the amount of PD-1
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 macrophage and PD-1
+
 lymphocyte contents remain as independent prognostic factors 




 macrophage and PD-1
+
 lymphocyte contents predict 
favorable survival in patients with primary testicular lymphoma. The findings implicate that the 
tumor microenvironment and PD-1 – PD-L1 pathway have a significant role in regulating treatment 





Primary testicular lymphoma (PTL) is a rare and aggressive lymphoid malignancy affecting mainly 
elderly men.  The biology of PTL is beginning to emerge,
1-7
 and the outcome has improved with the 
addition of anthracycline-based chemotherapy, central nervous system (CNS) targeted therapy 
and irradiation of the contralateral testis.
8-10
 Majority of PTLs represent diffuse large B-cell 
lymphoma (DLBCL) displaying more often non-germinal center B-cell (GCB) than GCB-like 
signatures.
11
 Somatic mutations in NF-kappa-B pathway genes, such as MYD88 and CD79B, as well 
as rearrangements of programmed cell death ligand (PD-L) -1 and -2 genes, have been shown to 
be enriched in PTL.
2, 4
 In addition, two stromal signatures associated with outcome have been 
described in primary, mainly nodal DLBCL patients treated with immunochemotherapy, forming a 




We have recently demonstrated that tumor-associated macrophages (TAMs) have a favorable 
prognostic impact on survival in DLBCL patients after immunochemotherapy,
13
 whereas other 
groups have investigated the role of programmed cell death-1 (PD-1) pathway in DLBCL.
14-18
 While 
PD-1 protein is expressed predominantly by activated tumor-infiltrating lymphocytes (TILs), its 
ligands (PD-L1 and PD-L2) have been shown to be expressed both by the tumor cells and the 
tumor microenvironment.
15, 19-21
  An unexpected feature has been that PD-L1 expression by the 
tumor-infiltrating myeloid and other immune cells can be more prevalent than PD-L1 expression 
by the tumor cells.
15, 19, 20
 Recently, it was also shown that the expression of PD-L1 not only by the 
tumor cells but also by the host cells plays a critical role in mediating the immunosuppressive 






In DLBCL, expression of PD-L1 by lymphoma cells has been associated with poor outcome.
14
 
Interestingly, 9p24.1/PD-L1/PD-L2 copy number alterations and additional translocations of these 
loci are frequent in PTLs (>50%), leading to increased expression of the PD-Ls,
4
 and possibly also to 
immune escape. Whether the expression of PD-1 and PD-Ls predict survival in PTL, and in which 
compartments, is unknown. 
 
With the aim of resolving the relative expression of checkpoint molecules by the tumor and host 
immune cells in patients with PTL, we examined B-cells, TAMs, TILs, and checkpoint molecules by 
using multiplex immunohistochemistry (mIHC),
22













 B-cells, and the checkpoint 





We identified 74 PTL patients with DLBCL histology diagnosed between the years 1987 and 2013 
from the pathology databases of the University Hospitals in Southern Finland. Histological 
diagnosis was established from surgical pretreatment tumor tissue according to current criteria of 
the World Health Organization (WHO) classification.
23
 Majority of the patients were treated with 
anthracycline based chemotherapy. About half of the patients received rituximab as a part of their 
treatment.  Contralateral testis was treated with surgical excision or irradiation for a minority of 
the patients. Patients were divided into three equal tertiles, based on the content of different 
immune cell subtypes (high, intermediate, low). The patient characteristics are described in more 
5 
 
detail in Table 1. The protocol and sampling were approved by the Institutional Review Boards, 
Ethics Committees and Finnish National Supervisory Authority for Welfare and Health. 
 
Multiplex immunohistochemistry (mIHC) 
Formalin-fixed, paraffin-embedded (FFPE) primary tumor tissues were collected from the local 
biobanks and reviewed to match the latest WHO classification.
23
 Selection of the cores on the 
tissue microarray (TMA) was based on the evaluation of a hematopathologist. TMA was 
constructed and the sections (3.5 µm) stained with 4-plex primary antibody panels (PD-L1, PD-L2, 
CD68, c-MAF; CD3, CD4, CD8, PD-1; CD20, CD163, PD1, PD-L1; Supplementary Table 1), followed 
by fluorescently labelled secondary antibodies and DAPI counterstain (nuclear stain). A more 
detailed description of the stainings is provided in the Supplementary Methods. Fluorescent 
images were acquired with AxioImager.Z2 (Zeiss, Germany). Machine-learning platform 
CellProfiler
24
 2.1.2 was used for cell segmentation, intensity measurements (upper quartile 
intensity) and immune cell classification. Different cell types were quantified as proportion to all 
cells (e.g. PD-L1⁺CD68⁺ implying the number of PD-L1⁺CD68⁺ TAMs from all cells in a TMA spot) or 
as a proportion to a specific cell subtype (e.g. PD-L1⁺CD68⁺/CD68⁺ implying the number of PD-
L1⁺CD68⁺ cells from all CD68⁺ TAMs). Spots with less than 5000 cells were excluded from the 
analysis, and data from duplicate spots from the same patient were merged.  
 
Gene expression analysis 
CD68, CD163, MAF, MS4A1 (CD20), CD274 (PD-L1), PDCD1LG2 (PD-L2), and PDCD1 (PD-1) mRNA 
levels were measured from 60 PTL samples using digital gene expression analysis with NanoString 




Survival definitions and statistical analyses 
Overall survival (OS) was defined as time between diagnosis and death from any cause, disease 
specific survival (DSS) as time between diagnosis and lymphoma related death, and progression 
free survival (PFS) as time between diagnosis and lymphoma progression or death from any cause. 
Statistical analyses were performed with IBM SPSS v.24.0 (IBM, Armonk, NY, USA). Differences in 
the frequency of prognostic factors between three patient groups were analyzed by Kruskal-Wallis 
test. Correlations between gene expression values and cell counts as well as between different 
immune cell subpopulations were tested with Spearman's rank correlation.  
 
Survival rates were estimated using the Kaplan–Meier method. Univariate and multivariate 
analyses were performed according to the Cox proportional hazards regression model. The 
potential bias due to duration of follow-up was assessed by Schoenfeld residual.  Probability 
values below 0.05 were considered statistically significant. All comparisons and all comparative 




Patient and treatment characteristics of the study cohort are shown in Table 1. Majority of the 
patients represented non-GCB phenotype, low stage, and had low/intermediate International 
Prognostic Index (IPI). Altogether 34 deaths, 24 relapses and 24 lymphoma-associated deaths 
occurred during the median follow-up of 67 months (range from 6.7 to 120 months). Five-year OS, 




Association of CD68, PD-L1 and PD-L2 encoding gene expression with survival 
First, we determined the gene expression of the macrophage markers (CD68, CD163 and MAF), 
checkpoint molecules CD274 (PD-L1), PDCD1LG2 (PD-L2) and PDCD1 (PD-1), and the B-cell marker 
MS4A1 (CD20). CD68 expression correlated positively with CD274 (rs=0.654, p<0.001), PDCD1LG2 
(rs=0.636, p<0.001), CD163 (rs=0.602, p<0.001), and MAF (rs=0.425, p=0.001) levels, and to a lesser 
extent with PDCD1 (rs=0.300, p=0.020), whereas no correlation between CD68 and MS4A1 
expression was found. Furthermore, the expression of CD68, CD274 and PDCD1LG2 genes 
analyzed as continuous variables, but not PDCD1, CD163 or MAF, translated into favorable survival 




 TAM content predicts favorable survival 
To explore the expression of the checkpoint molecules in the tumor cells and in the 
microenvironment in more detail, we analyzed the cell immunophenotypes with mIHC from a PTL 
TMA using four primary antibodies and DAPI (nuclear stain) simultaneously (Figure 1A-C; see also 
Table 1 for the TMA cohort used and Supplementary Table 1 for the antibody panels). The marker 
CD68 was used to identify all TAMs. Subpopulations of TAMs were defined by the presence and 
absence of CD163, c-MAF, PD-L1 and PD-L2 (Figure 1A-B, D). In addition, CD20 marker was used to 
identify lymphoma cells (Figure 1B). For detecting TILs, a panel with CD3, CD4, CD8, and PD1 
antibodies was used (Figure 1C).  
 
As a proof of concept, we found high agreement with the gene expression and the mIHC data 
when analyzing the quantities of CD68
+
 macrophages (rs=0.637, p<0.001), lymphoma cells 
(rs=0.704, p<0.001) and PD-L1
+
 cells (rs=0.710, p<0.001) (Supplementary Figure 1). The proportions 
of the different cell types in the tumor tissue are shown in Figure 1D. The most prominent non-
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malignant cell type was CD3
+
 T-lymphocyte (median 45%, range 5-97%).  TAM and PD-L1
+ 
cell 
contents showed a great variation between the samples (CD68
+
 TAMs, median 23%, range 3-81%; 
PD-L1
+
 cells, median 15%, range 0.01-100%), and a large proportion of lymphoma cells (median 
34%, range 0.1-100%) and TAMs (median 41%, range 0.1-99%) expressed PD-L1 . Due to a low 
proportion of PD-L2⁺ cells (0.06%) (data not shown), PD-L2 was excluded from further analyses.  
 
We further observed that high number of PD-L1
+
 cells, high proportion of PD-L1⁺CD68⁺ 











), associated with favorable OS when analyzed as continuous 
variables (Table 3). In order to use an objective cutoff we stratified the patients into three equal 
subgroups based on tertiles of the PD-L1⁺CD68⁺ macrophage counts (high, intermediate, low). The 
5-year OS and DSS rates were clearly worse for the patients with low number of PD-L1⁺CD68⁺ 
macrophages (≤4.75% corresponding to the lowest tertile of the patients) in comparison to the 
patients with intermediate or high numbers (>4.75%, 5-y OS, 39% vs 66%, p=0.014; 5-y DSS, 53% 
vs 76%, p=0.056; Figure 2A).  When PD-L1⁺CD68⁺ macrophage count was included in a multivariate 
analysis with IPI, both factors had independent prognostic value for OS (Table 4). In contrast, 
neither PD-L1
+
 lymphoma cells, PD-L1
+
CD68⁻ cells nor any other TAM phenotypes were 
significantly associated with survival (Table 3). When comparing the three PD-L1⁺CD68⁺ TAM 
subgroups (high, intermediate and low), no significant differences in age, molecular subtype, IPI 
score or treatments were observed (Table 1). However, high PD-L1⁺CD68⁺ macrophage count was 
associated with limited disease stage. When the patients treated in the pre-rituximab era were 
removed from the analyses, a trend towards worse survival was maintained for the patients with 
low number of PD-L1⁺CD68⁺ macrophages (≤5.97%, the lowest tertile; OS, p=0.093, 
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Supplementary Figure 2A). These results highlight the clinical relevance and possible functional 




 TILs with survival 
Given the prognostic value of PD-L1
+
 TAMs, we then determined their association with T-cells by 
mIHC. The marker CD3 was used to identify all T cells. Subpopulations of T cells were then defined 
by the presence and absence of CD4, CD8 and PD1 (Figure 1C-D).  As with CD4
+
 T-helper and CD8
+
 












 T-cell counts correlated with the PD-
L1
+
 TAM counts (Supplementary Table 2). Furthermore, as overall with T-cells
25
 high and 













 cells ≤5.7% corresponding to the lowest tertile vs other patients; 5-y OS, 34% vs 






 cells, ≤7.2% corresponding to the 
lowest tertile vs other patients; 5-y OS, 39% vs 65%, p=0.008; 5-y DSS, 43% vs 81%, p<0.001; 













counts maintained an independent association with OS (Table 4). When the patients treated in the 
pre-rituximab era were removed from the analyses, low number of PD-1
+
 T-cells maintained their 













 cells, ≤11.02%, the lowest tertile; OS, p=0.034; Supplementary Figure 2B-C).  
 
Discussion 
In this study, we applied mIHC and digital image analysis to a TMA comprised of PTL tissue from 74 
patients. We show that PTL microenvironment contains a heterogeneous TAM population. Among 
these, PD-L1
+















 TAM infiltration and survival, and both PD-L1
+
 TAMs and PD-1
+
 TILs 
emerged as independent indicators of survival for the patients with PTL. In contrast, neither PD-
L1
+
 lymphoma cells, other PD-L1
+
 cells than TAMs nor other TAM phenotypes correlated with 
survival. The findings highlight the specific roles of TAMs, TILs and PD1-PD-L1 axis in regulating 
survival and therapy resistance in PTL.  
 
mIHC is a novel technology enabling multi-parametric readout from a single tissue section. In 
our study, the simultaneous use of multiple markers is important in many ways. First, while PD-
L1 was found to be expressed both in TAMs and B-cells including lymphoma cells, the 
prognostic impact of PD-L1 positivity was restricted to TAMs. Thus, the use of just one marker 
would not be able to detect the survival association. Second, the spatial relationships between 
TILs, TAMs and lymphoma cells are retained in our experimental strategy, allowing for a more 
precise appreciation of their biological interactions. Third, since mIHC was performed on all 
evaluable PTL tissue areas on the TMA, thereby providing an overall snapshot of the PTL 
microenvironment, we can avoid a bias of earlier observations focusing only on hot spot areas 
of immune cell counts using single marker immunohistochemistry. However, it should be noted 
that while the overall infiltration of PD-L1
+
 TAMs and PD-1
+
 TILs had a significant impact on 
survival, their functional statuses remain to be explored. Combining our panel with other 
multiplex panels for immunoregulatory molecules, such as FoxP3, LAG-3 or IDO-1 and IDO-2, may 
be useful in the evaluation of response to immunotherapy. 
 
As described in a recent review article by Xu-Monette et al. the PD-L1 expression in the tumor 
microenvironment has not been previously well defined in B-cell lymphomas, and association with 
survival has not been demonstrated.
18
 PD-1 is a protein, which is classically upregulated upon 
11 
 
activation of T-lymphocytes. Interaction between PD-1 and PD-L1 was previously thought to 
induce immune tolerance by leading T-lymphocytes to apoptosis.
26
 Further studies have, however, 
revealed that the expression of PD-L1 on tumor cells can lead to immune escape, to T-cell 
exhaustion and a state of non-responsiveness, further enabling immune escape of the tumor 
cells.
27-29
 Moreover, in addition to binding to PD-1, PD-L1 and PD-L2 can also bind to CD80/B7-1 
(PD-L1)
30, 31
 and RGMb (PD-L2),
32





In addition to PD-L1, macrophages express PD-1.
33, 34
 Recently, Gordon and coworkers showed 
that PD-1 expression by TAMs inhibits phagocytosis and tumor immunity.
35
 In addition, they 
demonstrated that blockade of PD-1 – PD-L1 interaction increases macrophage phagocytosis, 
reduces tumor growth and lengthens survival in mouse models of colon cancer, suggesting PD-1 – 
PD-L1 pathway having a significant role in TAM function and tumor survival. 
 
Based on our findings, we suggest that the PD-1 - PD-L1 signaling between TAMs and TILs has 
clinical relevance in PTL. As PD-1 engagement on T-cells to its ligands has been linked to decreased 
anti-tumor immunity, and early experience on PD-1 blockade in PTL has shown promising results,
36
 
the association of high PD-L1
+
 TAM and PD-1
+
 T-cell count with favorable outcome in response to 
immunochemotherapy seems paradoxical. Yet, the interaction of PD-L1
+
 TAMs and PD-1
+
 T-cells 
might modify the tumor microenvironment in PTL, or otherwise promote an anti-tumor immune 
response following immunochemotherapy. 
 
In conclusion, we argue that high PD-L1⁺ TAM and PD-1
+
 T-cell counts correlate with each other 




 TAM scores seem to protect 
12 
 
the patients from progression and death, and identify a group of patients with favorable 
prognosis. Interestingly, apart from PD-L1⁺CD68
+
 TAMs, no association was found between other 
PD-L1⁺ cells or PD-L1⁻ TAMs and survival. Together, the data demonstrate that the PD-1 - PD-L1 
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Table 1. Patient and treatment characteristics. 
 
All n (%) PDL1+ PD-L1+ PD-L1+ 
CD68+ CD68+  CD68+ p 
low intermed. high 
Number of patients 74 25 (34) 24 (32) 25 (34) 
Median age (range) 70 (36-92) 68 (38-86) 73 (37-92) 66 (46-90) 
Age 
 ≤60, years 17 (23) 6 (24) 4 (17) 7 (28) 0.638 
 >60, years 57 (77) 19 (76) 20 (83) 18 (72) 
Molecular subgroup 
 GCBa 17 (23) 8 (32) 4 (17) 5 (20) 0.426 
 Non-GCB 56 (76) 17 (68) 20 (83) 19 (76) 
 NA 1 (1) 1 (4) 
Stage 
 I-II 47 (64) 10 (40) 16 (67) 21 (84) 0.002 
 III-IV 24 (32) 15 (60) 6 (25) 3 (12) 
 NA 3 (4) 2 (8) 1 (4) 
IPI score 
 0-2 50 (68) 13 (52) 17 (71) 20 (80) 0.065 
 3-5 20 (27) 11 (44) 5 (21) 4 (16) 
 NA 4 (5) 1 (4) 2 (8) 1 (4) 
CNS prophylaxis 36 (49) 9 (36) 11 (46) 16 (64) 0.137 
 IV prophylaxis 34 (46) 8 (32) 10 (42) 16 (64) 0.057 
 IT prophylaxis 7 (9) 2 (8) 3 (13) 2 (8) 0.856 
Contralateral testis treated 23 (31) 6 (24) 7 (29) 10 (40) 0.464 
 Irradiation 12 (16) 2 (8) 3 (13) 7 (28) 0.136 
 Surgical excision 11 (15) 4 (16) 4 (17) 3 (12) 0.884 
Anthracycline-based 
chemotherapy 60 (81) 18 (72) 21 (88) 21 (84) 0.305 
Treated with rituximab 35 (47) 9 (36) 11 (46) 15 (60) 0.237 
Relapse of contralateral testis 1 (1) 0 (0) 1 (4) 0 (0) 0.377 
CNS progression 9 (12) 4 (16) 4 (17) 1 (4) 0.312 
a
GCB, germinal center B-cell like; NA, not applicable; IPI, International prognostic Index; CNS, central nervous system; 





Table 2. Cox regression analysis at the univariate level showing association of gene expression 




 95% CI p 
CD68 0.505 0.290-0.881 0.016 
CD274 0.737 0.592-0.919 0.007 
PDCD1LG2 0.688 0.505-0.936 0.017 
PDCD1 0.846 0.659-1.088 0.192 
CD163 0.914 0.636-1.313 0.627 
MAF 0.899 0.551-1.466 0.668 
a
HR, hazard ratio; CI, confidence interval. Boldface font 




Table 3. Cox regression analysis at the univariate level showing association of cell 




 95% CI p 
PD-L1
+
 0.983 0.967-0.999 0.038 
CD20
+










 0.981 0.955-1.007 0.146 
CD68
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 0.734 0.518-1.041 0.083 
CD163
+





 0.989 0.969-1.010 0.298 
CD3
+














 0.042 0.003-0.537 0.015 
a
HR, hazard ratio; CI, confidence interval; PD-L1⁺CD68⁺ implies the number 
of PD-L1⁺CD68⁺ TAMs from all cells; PD-L1⁺CD68
+
/CD68⁺ implies the 
number of PD-L1⁺CD68⁺ TAMs from all CD68⁺ TAMs. Boldface font 




Table 4. Cox regression analysis at the multivariate level showing independent association of 









 2.214 1.054-4.650 0.036 







 2.275 1.054-4.909 0.036 







 2.654 1.261-5.586 0.010 







 2.259 1.075-4.748 0.031 
IPI 4.971 2.314-10.678 <0.001 
a





Figure 1. Characterization of cell immunophenotypes with mIHC. A-C) Representative images 
from 4-plex mIHC stainings. Panels (low, intermediate, and high) show representative images from 
the corresponding tertiles, based on the content of different immune cell subtypes. The insets 
highlight cells with higher magnification. PD-L1=blue, PD-L2=red, CD68=white, c-Maf=green (A); 
PD-L1=blue, CD163=red, CD20=white, PD1=green (B); CD3=blue, CD8=red, CD4=white, PD1=green 
(C). Scale bar 40 µm. D) Proportions of distinct immune cell subpopulations from all cells. PD-
L1⁺CD68⁺ indicating the content of PD-L1⁺ TAMs, PD-L1⁺CD163⁺ and PD-L1⁺CD68⁺c-Maf⁺ the 
content of PD-L1⁺ M2-polarized TAMs, PD-1⁺CD3⁺CD4⁺ and PD-1⁺CD3⁺CD8⁺ the content of PD-1⁺ 
TILs, and PD-L1⁺CD20⁺ the content of PD-L1⁺ lymphoma cells. 
 
Figure 2. Association of the immune cell subtypes with survival. A-C) Cell immunophenotypes 
were determined by mIHC from 74 PTL patients. Patients were stratified into three equal 
subgroups (high, intermediate and low) based on tertiles of PD-L1⁺CD68⁺ TAM, PD-1⁺CD3⁺CD4⁺ T-
cell, and PD-1⁺CD3⁺CD8⁺ T-cell counts. Kaplan-Meier plots depict survival differences between the 
PD-L1⁺CD68⁺ (A), PD-1⁺CD3⁺CD4⁺ (B), and PD-1⁺CD3⁺CD8⁺ (C) groups. P-values were determined 
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Multiplex Immunohistochemistry (mIHC) 
General. TMA blocks were cut in 3.5 µm sections on objective slides, which were dried overnight at 
+37°C and stored for short-term use at +4°C. All consecutive phases were performed in room 
temperature unless otherwise specified. Protein blocking and antibody incubations were performed 
in a humid chamber. Slides were washed three times with 0.1% Tween-20 (Thermo Fisher Scientific) 
diluted in 10 mM Tris-HCL buffered saline pH 7.4 (TBS) after peroxide block, antibody incubations, 
and fluorochrome reaction. The primary antibodies are listed in Supplementary Table 1. 
 
Tissue preparation. Slides were deparaffinized in xylene and rehydrated in graded ethanol series 
and H2O. Heat-induced epitope retrieval (HIER) was carried out in 10 mM Tris-HCl - 1 mM EDTA 
buffer (pH 9) in +99°C for 20 min (PT Module, Thermo Fisher Scientific, Waltham, MA). Peroxide 
activity was blocked in 0.9% H2O2 solution for 15 min, and protein block performed with 10% normal 
goat serum (TBS-NGS) for 15 min. 
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Fluorescence staining. Primary antibodies were diluted in protein blocking solution and incubated 
for 1 h 45 min. Thereafter, secondary anti-mouse or anti-rabbit horseradish peroxidase-conjugated 
(HRP) antibodies (Immunologic, Netherlands) diluted 1:1 with washing buffer were applied for 45 
min. Tyramide signal amplification (TSA) Alexa Fluor 488 (PerkinElmer, Waltham, MA) diluted in TBS 
was applied on the slides for 10 min. Primary antibodies were denaturated and enzymatic activity 
of secondary antibody HRP was quenched by repeating HIER. Thereafter, peroxide and protein block 
were repeated, followed by application of a different primary antibody, matching HRP-conjugated 
secondary antibody diluted 1:3 with washing buffer and TSA Alexa Fluor 555 (PerkinElmer). Again, 
HIER, peroxide block and protein block were repeated. Then, the slides were incubated with two 
additional primary antibodies immunized in different species overnight in +4°C. Next, AlexaFluor647 
and AlexaFluor750 fluorochrome-conjugated secondary antibodies (Thermo Fisher Scientific) 
diluted in 1:150 and DAPI (Roche) counterstain diluted 1:250 in washing buffer were applied for 45 
min. Last, we applied ProLong Gold mountant (Thermo Fisher Scientific) and a coverslip on the 
slides. 
 
Denaturation test. In order to minimize false positive signal from antibody cross-reactions during 
the mIHC procedure, we required that primary antibodies selected for mIHC must be completely 
denatured during the HIER step between staining rounds. Therefore, the denaturation properties 
of all primary antibodies were examined by performing an additional HIER step between primary 
and secondary antibody incubation. Antibodies not denaturing completely were detected with Cy5 
and Cy7 fluorescence probes, which do not require denaturation. 
Imaging. Fluorescent images were acquired with the AxioImager.Z2 (Zeiss, Germany) microscope 
equipped with Zeiss Plan-Apochromat 20x objective (NA 0.8), CoolCube1 CCD camera 
(MetaSystems, Germany), PhotoFluor LM-75 (89 North) metal-halide light source and Zeiss EPLAX 
VP232-2 power supply. DAPI, FITC, Cy3, Cy5, and Cy7 filters with compatible LED light sources were 
used and exposure times for all fluorescence channels were optimized visually for fluorescence 
imaging. Scanned images were acquired and were converted to JPEG2000 format (95% quality) for 
image analysis to reduce memory demand. 
 
Image analysis. The quality of gray-scale images of each TMA spot was first assessed and few images 
were discarded due to blurred focusing or unsuccessful image registration caused mainly by air 
bubbles in mounting media or shattered tissue, respectively. In the image analysis, DAPI-
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counterstained nuclei were segmented with adaptive Otsu thresholding, clumped objects separated 
by intensity patterns and cells segmented with nuclei contour expansion. We used the machine-
learning platform CellProfiler 2.1.2 for cell segmentation, intensity measurements (upper quartile 
intensity) and immune cell classification. We computed marker colocalization with the single-cell 
analysis software FlowJo v10 (FlowJo LLC.). The optimal gate coordinates were ensured by 
visualising matching cells with CellProfiler. 
 
Data analysis Spots with less than 5000 cells were excluded from the analysis. Different cell types 
were quantified as proportion to all cells (e.g. number of CD68⁺PD-L1⁺ TAMs to all cells in a TMA 








Supplementary Figure 1. 
 
Correlation between gene expression and immunohistochemistry (IHC). A-C) Correlations 
between MS4A1 (A), CD274 (B), and CD68 (C) mRNA levels with the corresponding cell counts in 
mIHC were determined by Spearman rank analysis. 
 
Supplementary Figure 2. 
 
 
Association of the immune cell subtypes with survival among the rituximab treated patients. Cell 
immunophenotypes were determined by mIHC from 35 PTL patients treated with rituximab. 
Patients were stratified into three equal subgroups (high, intermediate and low), based on tertiles 
of PD-L1⁺CD68⁺ TAM, PD-1⁺CD3⁺CD4⁺ T-cell, and PD-1⁺CD3⁺CD8⁺ T-cell counts, and the intermediate 
and high groups were merged based on the data from the whole cohort of 74 patients. Kaplan-
Meier plots depict survival differences between the PD-L1⁺CD68⁺ (A), PD-1⁺CD3⁺CD4⁺ (B), and PD-
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Supplementary tables 
Supplementary Table 1. Antibody panels. 
 
Theme GFP Cy3 Cy5 Cy7 
T-cells PD1a CD3 CD8 CD4 
Macrophages c-MAF PD-L1 PD-L2 CD68 
B-cells and macrophages PD-1 PD-L1 CD163 CD20 
aAntibodies: PD-1 (clone PDCD1) LsBio, CD3 (clone EP449E) Abcam, CD8 (clone C8/144B) Abcam, CD4 (clone EPR6855) 
Abcam, cMAF (clone EPR16484) Abcam, PD-L1 (clone E1L3N) Cell Signaling, PD-L2 (polyclonal) Sigma, CD68 (clone KP1) 
Abcam, CD20 (clone L26) BioSB, CD163 (clone EPR14643), Abcam. 
 
 
Supplementary Table 2. Correlations of the PD-1⁺ TIL and PD-L1⁺ TAM counts. 
  
Cell immunophenotype Spearman rho p-val 
CD3+CD4+ vs. PD-L1+CD68+ 0.699 <0.001 
CD3+CD8+ vs. PD-L1+CD68+ 0.640 <0.001 
PD-1+CD3+CD4+ vs. PD-L1+CD68+ 0.496 <0.001 
PD-1+CD3+CD8+ vs. PD-L1+CD68+ 0.461 <0.001 
 
